ARTICLE | Company News
ImmunoCellular, University of Pittsburgh deal
March 26, 2012 7:00 AM UTC
The university granted ImmunoCellular rights to IP related to EPH receptor A2 (EPHA2), a tyrosine kinase receptor. ImmunoCellular will have an exclusive, worldwide license to use the IP for ovarian and pancreatic cancers, and a non-exclusive, worldwide license for brain cancer. The company will use the IP to develop and commercialize its preclinical ICT-140 ovarian cancer vaccine. Details were not disclosed. ...